Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived CD5 CAR T cells for R/R T-ALL
NCT05032599Phase 1Terminated
- Sponsor
- Beijing Boren Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD5 CAR T cells in acute lymphoblastic leukemia (ALL), sponsored by Beijing Boren Hospital. Primary endpoints: Incidence and type of dose-limiting toxicity at 21 days and Incidence and severity of adverse events at 30 days. Started Sep 2021; status: terminated.
02
Drugs
CD5 CAR T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05032599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032599.